id: NEW:medication_formulation_treatment_flexibility_to_NEW:severe_maternal_morbidity_oud
name: Medication Formulation Treatment Flexibility for OUD in Pregnancy â†’ Severe Maternal Morbidity in
  OUD Population
from_node:
  node_id: NEW:medication_formulation_treatment_flexibility
  node_name: Medication Formulation Treatment Flexibility for OUD in Pregnancy
to_node:
  node_id: NEW:severe_maternal_morbidity_oud
  node_name: Severe Maternal Morbidity in OUD Population
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Treatment guidelines allow flexibility between buprenorphine formulations in pregnancy'
- 'Step 2: Pregnant individuals can continue pre-pregnancy medications without forced transitions'
- 'Step 3: Treatment continuity improves adherence and reduces treatment disruption'
- 'Step 4: Stable OUD treatment reduces complications associated with withdrawal or relapse'
- 'Step 5: Comparable maternal morbidity rates support safe flexible prescribing practices'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Loreen Straub et al. 2024. "Comparative Safety of In Utero Exposure to Buprenorphine
    Combined With Naloxone vs Buprenorphine Alone.." https://doi.org/10.1001/jama.2024.11501
  supporting_citations:
  - Additional citations require full-text access - Abstract references limited perinatal safety data
    on combination product
  - Additional citations require full-text access - Study builds on existing buprenorphine monotherapy
    pregnancy research
  - Additional citations require full-text access - Medicaid utilization data from 2000-2018 analyzed
  doi: 10.1001/jama.2024.11501
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Maternal morbidity rates were comparable between buprenorphine-naloxone (2.6%) and buprenorphine
  alone (2.9%) groups, with no statistically significant difference (RR 0.90, 95% CI 0.68-1.19).
quantitative_effects:
  effect_size:
    value: 0.9
    type: relative_risk
    ci_lower: 0.68
    ci_upper: 1.19
  sample_size: 8695
structural_competency:
  equity_implications: This finding supports policy-level changes to treatment guidelines. Restrictive
    policies requiring medication switching during pregnancy create structural barriers that may lead
    to treatment discontinuation and worse outcomes. Evidence supporting treatment flexibility empowers
    collaborative decision-making between providers and pregnant individuals.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.688062'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
